9 completed, 1 terminated. 10 Phase 3, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 10 | Completed 9, Terminated 1 |
| Phase 2 | 1 | Terminated 1 |
Follow fesoterodine: new trials by email Literature Review of fesoterodine trials Research Report on fesoterodine
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Extension Study of Fesoterodine for Overactive Bladder Syndrome in Children. Fesoterodine - Overactive Bladder | Phase 3 | Completed | Stéphane Bolduc | 26 | 2015-10-01 | 2019-07-30 |
| Comparison Between Desmopressin and Fesoterodine for Treatment of Night Time Voiding in Women Aged 65 and Older Desmopressin, Fesoterodine - Nocturia | Phase 2 / Phase 3 | Terminated | Mount Sinai Hospital, Canada | 4 | 2015-07-01 | 2016-11-15 |
| Fesoterodine and Oxybutynin XL for Overactive Bladder Syndrome in Children Fesoterodine, Oxybutynin XL - Overactive Bladder | Phase 3 | Completed | Stéphane Bolduc | 62 | 2014-12-01 | 2019-07-30 |
| Understanding the Response to Fesoterodine Through Genetic Evaluation in the Elderly (URGE) Fesoterodine Fumarate - Urge Urinary Incontinence | Phase 3 | Completed | University of North Carolina, Chapel Hill | 61 | 2012-09-01 | 2020-03-18 |
| Clinical Trial to Evaluate the Efficacy and Safety of Fesoterodine in Comparison to Tolterodine Extended Release(ER)in Patients With Overactive Bladder. Tolterodine ER, Placebo, Fesoterodine - Overactive Bladder | Phase 3 | Completed | Pfizer | 2417 | 2008-02-01 | 2011-02-02 |
| Long Term Study To Evaluate the Safety, Tolerability and Efficacy of Fesoterodine for Overactive Bladder. fesoterodine fumarate - Overactive Bladder | Phase 3 | Completed | Pfizer | 153 | 2008-02-01 | 2010-10-13 |
| Fesoterodine "add-on" Male Overactive Bladder Study Fesoterodine, Placebo - Overactive Bladder Syndrome | Phase 3 | Completed | Pfizer | 947 | 2007-11-01 | 2011-02-18 |
| Fesoterodine Flexible Dose Study Fesoterodine, Placebo - Overactive Bladder | Phase 3 | Completed | Pfizer | 896 | 2007-08-01 | 2009-09-15 |
| Clinical Trial to Evaluate the Efficacy and Safety of Fesoterodine in Comparison to Tolterodine for Overactive Bladder (OAB) fesoterodine fumarate, placebo, tolterodine tartrate - Overactive Bladder | Phase 3 | Completed | Pfizer | 1712 | 2007-04-01 | 2015-03-24 |
| A Clinical Trial To Assess Fesoterodine On Treatment Satisfaction And Symptom Improvement In Overactive Bladder Patients fesoterodine fumarate - Overactive Bladder | Phase 3 | Completed | Pfizer | 516 | 2007-01-01 | 2018-12-05 |
Urinary Bladder, Overactive (8) · Nocturia (1) · Urinary Incontinence, Urge (1)
Pfizer (6) · Stéphane Bolduc (2) · Mount Sinai Hospital, Canada (1) · University of North Carolina, Chapel Hill (1)
United States (6) · Canada (5) · Germany (4) · Poland (4) · South Korea (4) · Belgium (3) · Brazil (3) · Colombia (3) · Costa Rica (3) · Greece (3) · India (3) · Malaysia (3) · Singapore (3) · Slovakia (3) · Spain (3)
Harold P Drutz, MD (1) · Jennifer M Wu, MD (1) · Stephane Bolduc, MD (1)
PMID 37160401, PMID 35881009, PMID 19348029, PMID 21428726
R03AG042335 (1)